International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers

Journal of Nuclear Medicine

Volumn 54, Issue 5, 2013, Pages 683-690

  Biggi, Alberto ^a   Gallamini, Andrea ^a   Chauvie, Stephane ^a   Hutchings, Martin ^b   Kostakoglu, Lale ^c   Gregianin, Michele ^d   Meignan, Michel ^e   Malkowski, Bogdan ^f,g   Hofman, Michael S ^h   Barrington, Sally F ⁱ  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b Rigshospitalet   (Denmark)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e HENRI MONDOR HOSPITAL   (France)

^f Regional Oncology Centre Bydgoszcz   (Poland)

^g NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clinical trial; Concordance rate; Hodgkin lymphoma; Interim PET; Interpretation criteria

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXPERT; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; REPRODUCIBILITY; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

CLINICAL TRIAL; CONCORDANCE RATE; HODGKIN LYMPHOMA; INTERIM PET; INTERPRETATION CRITERIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CONSENSUS; DACARBAZINE; DOXORUBICIN; HODGKIN DISEASE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INFORMATION STORAGE AND RETRIEVAL; INTERNATIONALITY; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RESEARCH REPORT; VINBLASTINE;

EID: 84877115529     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.110890     Document Type: Article

References (20)

1. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52-59. (Pubitemid 43053523)
2. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91:475-481.
3. 18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746-3752.
4. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906-1914.
5. Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009;50:1257-1260.
6. Boellaard R, O'Doherty MJ, Weber WA, et al. PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181-200.
7. Chauvie S, Stancu A, Cerello P, Biggi A, Gallamini A. A clinical trial toolkit for diagnostic imaging exchange through the WEB [abstract]. Eur J Nucl Med Mol Imaging. 2009;36(suppl):S355.
8. Cohen J. A coefficient for agreement for nominal scales. Educ Psychol Meas. 1960;20:37-46.
9. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174. (Pubitemid 8054849)
10. Hayes AF, Krippendorff K. Answering the call for a standard reliability measure for coding data. Commun Methods Meas. 2007;1:77-89.
11. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Statistic Assoc. 1958;53:4547-4581.
12. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586. (Pubitemid 350002966)
13. Biggi A, Chauvie S, Bianchi A, et al. Interim PET in Hodgkin lymphoma: comparison of the different criteria to evaluate chemotherapy response [abstract]. Eur J Nucl Med Mol Imaging. 2009;36(suppl):S252.
14. Horning SJ, Juweid ME, Schoder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115:775-777.
15. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:1824-1833.
16. Meignan M, Itti E, Bardet S, et al. Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol. 2009;27:2739-2741.
17. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51:1337-1343.
18. 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging. 2012;39:4-12.
19. Gallamini A, Bianchi A, Borra A, et al. Dual-point FDG-PET: a novel scanning technique in Hodgkin lymphoma with bulky disease [abstract]. J Clin Oncol. 2012;30(suppl):8077P
20. Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006;107:2678-2687. (Pubitemid 44845624)